+1 (208) 254-6996 essayswallet@gmail.com


Create a 10- to 12-slide PowerPoint presentation that covers the following elements:

  • the anatomy and physiology of respiration (e.g., explain how breathing works);
  • the effects of the inhalation of smoke and E-cigarette vapor on gas exchange in the lungs;
  • specific diseases associated with smoking, both pulmonary and cardiovascular; and
  • lastly, based on what you know about E-cigarettes from the reading and your own research, defend or oppose the regulation of vaping products as traditional cigarettes.

PowerPoint slides should not contain a lot of text; use speaker notes to provide the details of your presentation. The general practice is to use no more than 5-6 bullet points per slide. The quality and depth of your speaker’s notes will be significantly factored into your grade.

Title and reference slides should be included. These do not count toward the 10- to 12-slide requirement. In addition to providing references on a reference slide, you need to cite your material in the slides as appropriate; use APA format for your references and citations.

Suggestions for Searching for Illustrations

Use at least 3 images in the presentation. When looking for illustrations to use, it is suggested that you type the subject into a search engine and click “images.” For your presentation, you are allowed to copy and paste images (being sure to cite and reference them). However, you are NOT allowed to copy and paste content, such as text, tables, and the like. As much as possible, your presentation needs to be in your own words. 


  • As directed in the tutorial above, pay attention to the background and font colors in your presentation—try to avoid using plain black text on a white background, but also avoid using colors that are visually difficult to see (such as yellow text on a light background) or that are unpleasant (such as red text on a yellow background). Strive for a pleasing, visually appealing appearance.
  • Reminder: The speaker notes should provide the detail and discussion of your presentation, and everything in the presentation should be in your own words, not copied and pasted from a source.

Case Report Review of Cases of E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and Brief Review of the Literature

Amr Essa ,1 Jeffrey Macaraeg,2 Nikhil Jagan,2 Daniel Kwon,3 Saboor Randhawa,1

Matthew Kruse,4 Stanley Thomas,2 Manasa Velagapudi,5 John Horne,5

Shraddha Narechania,2 Michael Kaster,2 Carrie Valenta,1 Venketraman Sahasranaman,2

and Douglas Moore2

1Creighton University School of Medicine, Department of Internal Medicine, Omaha, USA 2Creighton University School of Medicine, Department of Pulmonary, Critical Care, and Sleep Medicine, Omaha, USA 3Creighton University School of Medicine, Department of Pathology, Omaha, USA 4Creighton University School of Medicine, Department of Radiology, Omaha, USA 5Creighton University School of Medicine, Department of Infectious Diseases, Omaha, USA

Correspondence should be addressed to Amr Essa; amressa@creighton.edu

Received 4 December 2019; Accepted 28 April 2020; Published 15 June 2020

Academic Editor: Takeshi Terashima

Copyright © 2020 Amr Essa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Since the appearance of the E-Cigarette in the early 2000s, its industry, popularity, and prevalence have risen dramatically. In the past, E-Cigarette use with the vaping of nicotine or cannabis products had been associated with a few reported cases of lung injury. However, in 2019, thousands of cases of E-Cigarette or vaping product use-associated lung injury (EVALI) were reported in the United States. Evidence linked this outbreak with vaping of tetrahydrocannabinol (THC). We report two confirmed cases of EVALI and their associated clinical, radiologic, and pathologic features. This report supports the growing body of information regarding EVALI. It also discusses various substances, particularly vitamin E acetate, which has been suggested as a causative agent.

1. Introduction

The E-Cigarette is a battery-operated device used to produce an aerosol that is inhaled into the lungs, the composition of which is determined by the content of the E-Liquid. It usually delivers nicotine; however, it can be used to deliver other sub- stances such as tetrahydrocannabinol (THC), cannabidiol (CBD), and butane hash oils [1]. Since the introduction of E-Cigarette into the US market in 2007, there have been a few published and documented cases which describe lung disease in relation to vaping of nicotine or extracts of canna- bis, with the earliest documented in 2012 [2–5]. The summer of 2019 witnessed an alarming upsurge in the number of vaping-induced lung injury cases. The increasing mortality and associated morbidity catapulted it to national attention and led to the coining of the term E-Cigarette or vaping

product use-associated lung injury (EVALI) [6]. Despite the prevalence of vaping in the US and other developed coun- tries, such as the United Kingdom, wherein 3.2 million peo- ple vape, an outbreak of this magnitude had never occurred previously [7]. Collaboration between the Centers for Disease Control and Prevention (CDC), state health departments, the medical communities, and the public is ongoing to further delineate the nature of this outbreak and the causative agents. An association between EVALI and non-nicotine-containing liquids has been suggested. Although it remains unclear which group of chemicals are involved, vitamin E acetate recently has been implicated. In this report, we highlight two cases of EVALI which were diagnosed and treated at our institution. We further discuss the clinical, radiologic, and pathologic features, with a brief review of the current body of published literature.

Hindawi Case Reports in Pulmonology Volume 2020, Article ID 1090629, 7 pages https://doi.org/10.1155/2020/1090629https://orcid.org/0000-0003-1310-643Xhttps://creativecommons.org/licenses/by/4.0/https://creativecommons.org/licenses/by/4.0/https://creativecommons.org/licenses/by/4.0/https://doi.org/10.1155/2020/1090629

2. Case Presentation

2.1. Case 1. A 42-year-old man with no underlying medical problems presented with a two-week history of worsening nonproductive cough, subjective fever, chills, and diaphore- sis. The history was significant for vaping THC once or twice weekly for the last one year. He reported no use of tobacco, alcohol, or illicit drugs. He denied any recent travel, and he had a desk job with no reported occupational exposures. On presentation, he was hypoxic with an oxygen saturation of 85% on room air that improved with one liter of oxygen via nasal cannula. He was afebrile and hemodynamically sta- ble. Physical exam was significant for diffuse bilateral rales. Chest radiograph (CXR) revealed diffuse interstitial pro- minence (Figure 1). A subsequent computed tomography (CT) scan of the chest revealed extensive symmetric ground-glass opacities in all lobes with interlobular septal thickening and subpleural sparing (Figures 2 and 3). He was started on broad-spectrum antimicrobial therapy with azithromycin, ceftriaxone, and levofloxacin to treat poten- tially bacterial pneumonia, all of which was discontinued after cultures were sterile (Table 1). Bronchoalveolar lavage (BAL) of the right middle lobe was performed. A transbron- chial tissue biopsy of the left upper lobe (upper division and lingula) (Figures 4 and 5) revealed benign bronchial mucosa without significant pathologic abnormality. Since an infec- tious etiology was ruled out, he was discharged on predni-

sone 40mg daily with tapering over four weeks. He reported improvement of symptoms within one week after discharge.

2.2. Case 2. A 21-year-old man with a history of exercise- induced asthma presented with a one-week history of worsening productive cough, dyspnea, nausea, vomiting, and malaise. He stated that he vaped THC once every hour while awake for the last three months and once daily for the previous year. He reported no use of tobacco prod- ucts, alcohol, or other illicit drugs. He reported recent travel to the Southwestern United States and Minnesota the month prior to hospitalization. He denied any occupa- tional exposure. On presentation, he was hypoxic with an oxygen saturation of 88%, which improved with two liters of oxygen via nasal cannula. He was afebrile and hemody- namically stable. Physical exam was significant for bibasilar crackles. CXR on admission showed patchy alveolar opacities in the mid and lower lungs bilaterally (Figure 6). CT chest demonstrated basal-predominant bilateral ground-glass opacities with subpleural sparing, in addition to pneumome- diastinum and slightly prominent bilateral hilar lymph nodes (Figures 7 and 8). He was started on broad-spectrum antimi- crobial therapy with vancomycin, piperacillin-tazobactam, azithromycin, and fluconazole with coverage to treat poten- tial coccidioidomycosis and presumed bacterial pneumonia, all of which were discontinued after cultures were sterile (Table 1). BAL of the right lower lobe revealed macro- phages with neutrophils and lymphocytes (Figure 9). A transbronchial tissue biopsy of the right lower lobe showed an acute fibrinous and organizing pneumonia pattern with no prominent eosinophils, granulomas, or malignancy (Figures 10–13). Six-minute walk before discharge was notable for oxygen desaturation with activity, and subse- quently, he was discharged on one-liter oxygen via nasal cannula and prednisone 40mg daily tapering over four weeks. He reported a resolution of his symptoms at the time of his clinic follow-up visit about six weeks following discharge. Repeat chest high-resolution CT (HRCT) at that time showed remarkable improvement in the aeration of his

Figure 1: Case 1 CXR on presentation.

Figure 2: Case 1 chest CT scan on presentation (axial view).

Figure 3: Case 1 chest CT scan on presentation (coronal view).

2 Case Reports in Pulmonology

lungs and resolution of the bilateral ground-glass opacities (Figures 14 and 15).

3. Discussion

Since the 2000s, when E-Cigarette made its initial appear- ance, the vaping industry has shown rapid emergence. Its popularity and prevalence have been driven by an appar-

ent improved nicotine delivery system with attractive fea- tures for users and a wide variety of flavors. E-Cigarette marketing-related expenditure in the United States increased from $3.6 million in 2010 to $125 million in 2014 [7]. At the same time, the prevalence of vaping has been on the rise, with

Table 1: Lab work on admission.

Case 1 Case 2

Infectious workup

White cell count 11.3K/μl 14.3K/μl

Sedimentation rate (ESR) 80mm/hr 91mm/hr

Procalcitonin 0.21 ng/ml 0.40 ng/ml

Legionella urine antigen Negative Negative

Pneumococcal urine antigen Negative Negative

Histoplasma urine antigen Negative Negative

Blood culture for aerobic & anaerobic growth

Negative Negative

Respiratory viral pathogen screen Negative Negative

Sputum culture Negative Negative

Sputum AFB smear Negative Negative

HIV AG/AB Negative Negative

ANCA Negative Negative

1,3-b-d-Glucan Negative Negative

BAL cell count and differentials Normal Normal

BAL total nucleated cells 440/μl 640/μl

BAL RBCs <10.000/μl <10.000/μl BAL neutrophils 49% 39%

BAL lymphocytes 28% 5%

BAL monocytes 17% 8%

BAL phagocytes 6% 48%

BAL fungal culture with special Negative Negative

BAL vulture viral reflex Negative Negative

BAL bacterial culture Negative Negative

BAL Aspergillus antigen Negative Negative

Miscellaneous workup

Lyme disease serology Negative

Rapid strep A Negative

West Nile antibodies Negative

Glomerular basement membrane (GBM) antibodies


Mononucleosis screen Negative

Complement levels Normal

LDH level Normal

ProBNP 74 pg/ml

CRP >375mg/l Coccidioides antibodies Negative

Hypersensitivity pneumonitis panel Negative

BAL AFP culture and smear Negative

BAL PCR for Legionella Negative

Figure 4: Case 1 transbronchial biopsy of upper division of left upper lobe with benign bronchial mucosa.

Figure 5: Case 1 transbronchial biopsy of left lingula with benign bronchial mucosa.

Figure 6: Case 2 CXR on presentation.

3Case Reports in Pulmonology

more than a quarter (25.4%) of 12th-grade students in 2019 saying that they had vaped in the last 30 days, more than double the rate in 2017 [8]. A study developed to describe advertising claims made on branded E-Cigarette reported that it is marketed as a healthier and cheaper alternative to conventional smoking. And the appeal of the wide array of flavors, perception of modernity, enhanced social appearance and celebrity use, and avoidance of smoking policy were appealing to many [9].

Based on largely observational data on the current out- break, the majority of reported cases were young males [10–13]. The commonly reported clinical symptoms include fever, chills, and a headache. Respiratory symptoms include shortness of breath, cough, and chest pain. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdomi- nal pain [10–13]. Fever was present in 29%, tachycardia in 64%, and tachypnea in 43%, with oxygen saturation < 88% in 31% of the cases in one report [10]. There are no clear guidelines regarding the management of EVALI, although glucocorticoids and empiric systemic antimicrobial therapy have been prescribed in the majority of cases [10, 11, 13]. The improvement in respiratory symptoms has been attrib- uted to glucocorticoids [10, 12].

Figure 7: Case 2 chest CT scan on presentation (axial view).

Figure 8: Case 2 chest CT scan on presentation (coronal view).

Figure 9: Case 2 bronchioalveolar lavage (BAL) of right lower lobe. Macrophages (red arrow) and neutrophils (yellow arrows).

Figure 10: Case 2 transbronchial biopsy of right lower lobe. Macrophages containing blackish brown pigmented particles (red arrows).

Figure 11: Case 2 transbronchial biopsy of right lower lobe with multiple neutrophils.

Figure 12: Case 2 transbronchial biopsy of right lower lobe. Eosinophilic fibrin exudate between cells, typical for pneumonia.

4 Case Reports in Pulmonology

86% of the 867 EVALI patients report using THC- containing products in the three months preceding symptom onset with mild elevations in white cell count, sedimentation rate, and procalcitonin [14]. Both of our patients were young males who vaped THC and met a “confirmed” diagnosis of

EVALI set by the CDC. The clinical characteristics and pre- sentation were consistent with previously reported cases [15].

A wide range of imaging patterns has been described in EVALI [16, 17], including hypersensitivity pneumonitis, dif- fuse alveolar damage, acute lung injury, acute eosinophilic pneumonia, organizing pneumonia, lipoid pneumonia, and giant cell interstitial pneumonia. Imaging obtained during the acute phase for both our patients demonstrated diffuse ground-glass opacities slightly more prominent at the lower lung zones, with subpleural and peribronchovascular spar- ing. Our patients had a pattern most consistent with organiz- ing pneumonia, which has been described in the EVALI literature. Peribronchovascular sparing, as was seen in our patients, is not a well-described feature that may represent clearing by the peribronchovascular lymphatics related to a subacute process with vaping. Of note, 100% of the cases in the report of 53 cases had bilateral infiltrates on chest radio- graph or CT [10].

The pathology of EVALI continues to be poorly under- stood with no specific histopathological findings. A recent review described lung biopsies from 17 patients with either a “confirmed” or “probable” diagnosis of EVALI. All showed a pattern of acute lung injury, including acute fibrinous pneumonitis, diffuse alveolar damage, or organizing pneu- monia. While other reports suggested an exogenous lipoid pneumonia-like process, the authors suggested that the pat- terns resemble a chemical pneumonitis [18]. Nevertheless, both findings do not provide clarity while making a histolog- ical diagnosis for EVALI. Our second patient showed similar histopathology, as described in the literature, with findings suggestive of acute pneumonia/inflammation with macro- phages containing blackish brown pigmented material. Our first patient did not show any histological pattern of lung injury despite meeting a “confirmed” diagnosis of EVALI by the CDC [15]. However, the biopsy showed predomi- nantly bronchial mucosa and not adequate alveolar tissues; thus, whether the patient had normal lung histopathology is inconclusive.

E-Cigarette aerosol contains different harmful sub- stances, including carbonyls, volatile organic compounds, toluene, benzene, and heavy metals [19, 20]. Their constitu- ents undergo thermal decomposition by the metallic coils, which then release new compounds that can be toxic [21]. In one study, E-Cigarette products contained microbial toxins, which included endotoxin concentrations above the limit of detection (LOD) in 17 of the 75 products tested and glucan concentrations greater than the LOD in 61 of 75 products tested [22]. Certain pesticides, such as chlorpyrifos ethyl and trifluralin, have been detected in high concentra- tions in some E-Liquid samples [23].

Triantafyllou et al. described several proposed mecha- nisms of EVALI, which include alteration in the expression of bronchial epithelial proteins, inducing airway remodeling, and macrophage activation [12]. Marijuana smoke inhala- tion has been associated with damage to the pulmonary epi- thelial barrier, and even the flavoring component has been linked to lung injury [23]. Compounds such as diacetyl, 2,3-pentanedione, and acetoin can impair ciliary function and have been evaluated and linked to bronchiolitis

Figure 13: Case 2 transbronchial biopsy. Macrophages (red arrows) and neutrophils (yellow arrows) in a background of exudative material.

Figure 14: Case 2 chest CT scan 6 weeks post discharge (axial view).

Figure 15: Case 2 chest CT scan 6 weeks post discharge (coronal view).

5Case Reports in Pulmonology

obliterans, the popular term being “popcorn lung,” which causes severe respiratory diseases among workers inhaling these heated vapors [24–26].

Recently, samples of THC-containing products have been analyzed to identify the potential contributing sub- stance resulting in harmful effects on the lung. Different sub- stances were identified, which have included vitamin E acetate, medium-chain triglyceride oil (MCT oil), and other lipids [27] (Personal communication, D.T. Heitkemper, FDA Forensic Chemistry Center, November 2019). Vitamin E acetate, in particular, has been identified in the majority of the THC cartridge samples tested in various states and facilities [14, 28]. Vitamin E acetate is a compound that is used as an additive to E-Cigarette and as a thickening agent in THC products [29]. Vitamin E acetate was further impli- cated when a breakthrough report from CDC on November 8, 2019, showed that it was detected in 100% of the BAL sam- ples of the 29 cases with EVALI that were sent to the CDC from 10 different states across the United States, while THC was identified in 82% and nicotine in 62% of the samples. Of note, no other suspected substances (plant oils, MCT oil, petroleum distillates, and diluent terpenes) were detected in those 29 BAL samples [30]. Inhaling vitamin E is not as benign as ingesting vitamin E, as it can impair lung function [31]. This provides strong evidence that vitamin E acetate might be a potential agent, though further studies are needed to validate this link.

4. Conclusion

EVALI can be devastating and even fatal, as was seen by the recent outbreak. Although various substances have been investigated, vitamin E acetate appears to be a risk factor. More data is needed to establish causality. With this report of two cases with radiologic and pathological findings, we hope to enrich the growing database and increase our knowl- edge of this disorder.


EVALI: E-Cigarette or vaping product use-associated lung injury

THC: Tetrahydrocannabinol CBD: Cannabidiol CDC: Centers for Disease Control and Prevention CXR: Chest X-ray CT: Computed tomography BAL: Bronchoalveolar lavage HRCT: High-resolution computed tomography ESR: Sedimentation rate ANCA: Antineutrophil cytoplasmic antibody AFB: Acid-fast bacillus HIV: Human immunodeficiency virus AG: Antigen AB: Antibody GBM: Glomerular basement membrane LDH: Lactate dehydrogenase BNP: B-Natriuretic peptide PCR: Polymerase chain reaction

LOD: Limit of detection MCT: Medium-chain triglyceride.


Consent for publication of patient information was obtained.

Conflicts of Interest

The authors declare no conflict of interest or financial disclosure.


We thank Laurel Preheim, MD, for assistance with editing and formatting.


[1] A. K. Breitbarth, J. Morgan, and A. L. Jones, “E-cigarettes—an unintended illicit drug delivery system,” Drug and Alcohol Dependence, vol. 192, pp. 98–111, 2018.

[2] L. McCauley, C. Markin, and D. Hosmer, “An unexpected consequence of electronic cigarette use,” Chest, vol. 141, no. 4, pp. 1110–1113, 2012.

[3] C. R. Gilbert, M. Baram, and N. C. Cavarocchi, ““Smoking wet”: respiratory failure related to smoking tainted marijuana cigarettes,” Texas Heart Institute Journal, vol. 40, no. 1, pp. 64–67, 2013.

[4] H. R. T. Hashmi, R. Duncalf, and M. Khaja, “A case report of cannabis induced hemoptysis,” Medicine, vol. 95, no. 13, p. e3232, 2016.

[5] M. Monfort, A. Larakeb, and F. Gouraud, “Hemoptysis in a young man smoking cannabis,” Archives de Pediatrie, vol. 20, no. 6, pp. 637–639, 2013.

[6] US Centers for Disease Control and Prevention, Investigation notice: outbreak of lung illness associated with using e- cigarette products, 2019.

[7] S. A. Glantz and D. W. Bareham, “E-cigarettes: use, effects on smoking, risks, and policy implications,” Annual Review of Public Health, vol. 39, pp. 215–235, 2018.

[8] G. Iacobucci, “Vaping among US teens has doubled since 2017,” BMJ, vol. 366, article l5653, 2019.

[9] R. A. Grana and P. M. Ling, ““Smoking revolution”: a content analysis of electronic cigarette retail websites,” American Jour- nal of Preventive Medicine, vol. 46, no. 4, pp. 395–403, 2014.

[10] J. E. Layden, I. Ghinai, I. Pray et al., “Pulmonary illness related to e-cigarette use in Illinois and Wisconsin — Final report,” New England Journal of Medicine, vol. 382, no. 10, pp. 903– 916, 2020.

[11] G. A. Triantafyllou, P. J. Tiberio, R. H. Zou et al., “Vaping- associated acute lung injury: a case series,” American Journal of Respiratory and Critical Care Medicine, vol. 200, no. 11, pp. 1430-1431, 2019.

[12] S. D. Maddock, M. M. Cirulis, S. J. Callahan et al., “Pulmonary lipid-laden macrophages and vaping,” New England Journal of Medicine, vol. 381, no. 15, pp. 1488-1489, 2019.

[13] N. Lewis, K. McCaffrey, K. Sage et al., “E-cigarette use, or vap- ing, practices and characteristics among persons with associ- ated lung injury—Utah, April–October 2019,” Morbidity and Mortality Weekly Report, vol. 68, no. 42, pp. 953–956, 2019.

6 Case Reports in Pulmonology

[14] E. D. Moritz, L. B. Zapata, A. Lekiachvili et al., “Update: char- acteristics of patients in a national outbreak of e-cigarette, or vaping, product use–associated lung injuries—United States, October 2019,” Morbidity and Mortality Weekly Report, vol. 68, no. 43, pp. 985–989, 2019.

[15] https://www.cdc.gov/tobacco/basic_information/e-cigarettes/ assets/2019-Lung-Injury-Surveillance-Case-Definition-508 .pdf.

[16] T. S. Henry, J. P. Kanne, and S. J. Kligerman, “Imaging of vaping-associated lung disease,” New England Journal of Med- icine, vol. 381, no. 15, pp. 1486-1487, 2019.

[17] T. S. Henry, S. J. Kligerman, C. A. Raptis, H. Mann, J. W. Sechrist, and J. P. Kanne, “Imaging findings of vaping- associated lung injury,” American Journal of Roentgenology, vol. 214, no. 3, pp. 498–505, 2020.

[18] Y. M. Butt, M. L. Smith, H. D. Tazelaar et al., “Pathology of vaping-associated lung injury,” New England Journal of Medi- cine, vol. 381, no. 18, pp. 1780-1781, 2019.

[19] R. Grana, N. Benowitz, and S. A. Glantz, “E-cigarettes: a scientific review,” Circulation, vol. 129, no. 19, pp. 1972– 1986, 2014.

[20] E. Kamilari, K. Farsalinos, K. Poulas, C. G. Kontoyannis, and M. G. Orkoula, “Detection and quantitative determina- tion of heavy metals in electronic cigarette refill liquids using total reflection X-ray fluorescence spectrometry,” Food and Chemical Toxicology, vol. 116, pp. 233–237, 2018.

[21] I. Burstyn, “Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks,” BMC Public Health, vol. 14, no. 1, p. 18, 2014.

[22] M.-S. Lee, J. G. Allen, and D. C. Christiani, “Endotoxin and (1→3)-β-D-glucan contamination in electronic cigarette products sold in the United States,” Environmental Health Per- spectives, vol. 127, no. 4, article 047008, 2019.

[23] N. Beauval, S. Antherieu, M. Soyez et al., “Chemical evaluation of electronic cigarettes: multicomponent analysis of liquid refills and their corresponding aerosols,” Journal of Analytical Toxicology, vol. 41, no. 8, pp. 670–678, 2017.

[24] E. Gil, B. Chen, E. Kleerup, M. Webber, and D. P. Tashkin, “Acute and chronic effects of marijuana smoking on pulmo- nary alveolar permeability,” Life Sciences, vol. 56, no. 23-24, pp. 2193–2199, 1995.

[25] J. G. Allen, S. S. Flanigan, M. LeBlanc et al., “Flavoring chemi- cals in e-cigarettes: diacetyl, 2, 3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail- flavored e-cigarettes,” Environmental Health Perspectives, vol. 124, no. 6, pp. 733–739, 2016.

[26] H.-R. Park, M. O’Sullivan, J. Vallarino et al., “Transcriptomic response of primary human airway epithelial cells to flavoring chemicals in electronic cigarettes,” Scientific Reports, vol. 9, no. 1, pp. 1400–1411, 2019.

[27] https://fox17.com/news/nation-world/cdc-finds-vitamin-e- acetate-as-potential-cause-of-vaping-illnesses.

[28] L. Sun, Vaping lung injuries top 1,000 cases as deaths rise to 18. The Washington Post, 2019, https://www.washingtonpost .com/health/2019/10/03/vaping-lung-injuries-top-cases- deaths-rise.

[29] D. Downs, Amid Vape Pen Lung Disease Deaths: What Exactly Is Vitamin E Oil?, Seattle, WA, USA, Leafly, 2019.

[30] https://www.cdc.gov/mmwr/volumes/68/wr/mm6845e2 .htm?s_cid=mm6845e2_w.

[31] J. B. Massey, H. S. She, and H. J. Pownall, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochemical and Biophysical Research Communications, vol. 106, no. 3, pp. 842–847, 1982.

7Case Reports in Pulmonologyhttps://www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdfhttps://www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdfhttps://www.cdc.gov/tobacco/basic_information/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdfhttps://fox17.com/news/nation-world/cdc-finds-vitamin-e-acetate-as-potential-cause-of-vaping-illnesseshttps://fox17.com/news/nation-world/cdc-finds-vitamin-e-acetate-as-potential-cause-of-vaping-illnesseshttps://www.washingtonpost.com/health/2019/10/03/vaping-lung-injuries-top-cases-deaths-risehttps://www.washingtonpost.com/health/2019/10/03/vaping-lung-injuries-top-cases-deaths-risehttps://www.washingtonpost.com/health/2019/10/03/vaping-lung-injuries-top-cases-deaths-risehttps://www.cdc.gov/mmwr/volumes/68/wr/mm6845e2.htm?s_cid=mm6845e2_whttps://www.cdc.gov/mmwr/volumes/68/wr/mm6845e2.htm?s_cid=mm6845e2_w

Copyright of Case Reports in Pulmonology is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder’s express written permission. However, users may print, download, or email articles for individual use.

  • Review of Cases of E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) and Brief Review of the Literature
  • 1. Introduction
  • 2. Case Presentation
    • 2.1. Case 1
    • 2.2. Case 2
  • 3. Discussion
  • 4. Conclusion
  • Abbreviations
  • Consent
  • Conflicts of Interest
  • Acknowledgments